NYSE:MORMorphoSys Stock Price, Forecast & News

MorphoSys' stock was trading at $25.26 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, MOR shares have increased by 29.1% and is now trading at $32.62. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MorphoSys.

MorphoSys is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for MorphoSys.

MorphoSys AG Unsponsored ADR (NYSE:MOR) announced its quarterly earnings results on Wednesday, May, 6th. The company reported $1.68 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $1.64. The firm had revenue of $277.09 million for the quarter, compared to analysts' expectations of $146.03 million. View MorphoSys' earnings history.

News stories about MOR stock have trended very positive on Monday, InfoTrie Sentiment reports. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MorphoSys earned a news impact score of 4.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news aboutMorphoSys.

Some companies that are related to MorphoSys include Vir Biotechnology (VIR), Cronos Group (CRON), BTG (BTG), Abcam (ABC), Kodiak Sciences (KOD), Genus (GNS), Mesoblast (MSB), Polynovo (PNV), NGM Biopharmaceuticals (NGM), Concordia International (CXR), Clinuvel Pharmaceuticals (CUV), BELLUS Health (BLU), Trillium Therapeutics (TRIL), Aptose Biosciences (APS) and PureTech Health (PRTC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other MorphoSys investors own include Immunomedics (IMMU), Alnylam Pharmaceuticals (ALNY), Stemline Therapeutics (STML), TG Therapeutics (TGTX), Zymeworks (ZYME), ACADIA Pharmaceuticals (ACAD), Agenus (AGEN), Amarin (AMRN), argenx (ARGX) and Arena Pharmaceuticals (ARNA).

(MOR) raised $200 million in an initial public offering (IPO) on Thursday, April 19th 2018. The company issued 8,300,000 shares at a price of $24.12 per share. Goldman Sachs, J.P. Morgan and Leerink Partners served as the underwriters for the IPO and Berenberg Capital Markets and JMP Securities were co-managers.

MorphoSys trades on the New York Stock Exchange (NYSE) under the ticker symbol "MOR."

Shares of MOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MOR stock can currently be purchased for approximately $32.62.

MorphoSys has a market capitalization of $4.29 billion.

The official website for MorphoSys is www.morphosys.com.

The company can be reached via phone at 49 89 89927 0.